Boston (May 2, 2024)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized...
Company to host conference call and webcast on Thursday, May 16th at 8:30am EDT LYON, France, May 2, 2024 --...
Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)PRINCETON, N.J., May 02, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB)...
NASHUA, N.H., May 02, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global leader in clinically proven AI-powered cancer...
Aiming to Combat Skin Cancer with Community Shade InitiativesOTTAWA, May 02, 2024 (GLOBE NEWSWIRE) -- The Canadian Dermatology Association (CDA)...
BASKING RIDGE, N.J., May 02, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage...
Media Release Novel triple combination of efti with radiotherapy and anti-PD-1 therapy is well tolerated and has led to encouraging...
Reported positive data from three-month evaluable CIS patients treated across ongoing TARA-002 clinical program in NMIBCPreliminary data from six-month evaluable...
KNOXVILLE, TN, May 02, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced that...
CTIM-76 Phase 1 clinical trial to focus on CLDN6-positive gynecologic and testicular cancers Company expects to enroll first patient in...
Webcast and Conference Call To be Held Thursday, May 9th, 2024, 8:30 am ETNEW YORK, May 02, 2024 (GLOBE NEWSWIRE)...
CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on...
First long-term data presentation from Parts 1 and 2 of the Phase 1 clinical trial of sudocetaxel zendusortide in solid...
End-of-treatment data from two Phase 2a combination clinical trials with imdusiran to be presented at the EASL Congress in June...
- Presented cardiac magnetic resonance (CMR) imaging evidence consistent with clinical improvement observed in patients with transthyretin amyloid cardiomyopathy (ATTR-CM)...
VANCOUVER, BC / ACCESSWIRE / May 2, 2024 / MindBio Therapeutics Corp. (CSE:MBIO)(Frankfurt:WF6), (the "Company" or "MindBio"), a clinical stage...
LUND, SWEDEN / ACCESSWIRE / May 2, 2024 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) Positive start to an important yearJANUARY - MARCH...
NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness,...
Hamilton, Bermuda, May 01, 2024 (GLOBE NEWSWIRE) -- Continued expansion of IP portfolio related to RNA delivery Treatment of rheumatoid...
- The Company Filed IP Protection Related to the ASXL1 Mutation, a Highly Prevalent Gene Mutation in Myeloid Malignancies and...